Andres Sirulnik

1.4k total citations
21 papers, 990 citations indexed

About

Andres Sirulnik is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, Andres Sirulnik has authored 21 papers receiving a total of 990 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Genetics, 11 papers in Hematology and 9 papers in Molecular Biology. Recurrent topics in Andres Sirulnik's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (10 papers), Chronic Myeloid Leukemia Treatments (6 papers) and Acute Myeloid Leukemia Research (5 papers). Andres Sirulnik is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (10 papers), Chronic Myeloid Leukemia Treatments (6 papers) and Acute Myeloid Leukemia Research (5 papers). Andres Sirulnik collaborates with scholars based in United States, United Kingdom and Switzerland. Andres Sirulnik's co-authors include Jean‐Jacques Kiladjian, Claire Harrison, Alessandro M. Vannucchi, Giovanni Barosi, Heinz Gisslinger, Francesco Passamonti, Tiziano Barbui, Laurent Knoops, Francisco Cervantes and Deborah Hunter and has published in prestigious journals such as Blood, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Andres Sirulnik

21 papers receiving 971 citations

Peers

Countries citing papers authored by Andres Sirulnik

Since Specialization

Citations

This map shows the geographic impact of Andres Sirulnik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andres Sirulnik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andres Sirulnik more than expected).

Fields of papers citing papers by Andres Sirulnik

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andres Sirulnik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andres Sirulnik. The network helps show where Andres Sirulnik may publish in the future.

Co-authorship network of co-authors of Andres Sirulnik

This figure shows the co-authorship network connecting the top 25 collaborators of Andres Sirulnik. A scholar is included among the top collaborators of Andres Sirulnik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andres Sirulnik. Andres Sirulnik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy 2020 ·Blood ·Rajat Bannerji, John N. Allan, Jon Arnason, Jennifer R. Brown, Ranjana H. Advani, Stephen M. Ansell, Susan O’Brien, Johannes Duell, Peter Martin, Robin Joyce, Jingjin Li, Dina M. Flink, Min Zhu, David M. Weinreich, George D. Yancopoulos, Andres Sirulnik, Aafia Chaudhry, Srikanth Ambati, Max S. Topp	88
2	MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis 2019 ·Expert Opinion on Biological Therapy ·Pieter Fokko van Loo, Basav N. Hangalapura, Soley Thordardottir, John D. Gibbins, Henrike Veninga, Linda Hendriks, Arjen Kramer, Rob C. Roovers, (unknown), John de Kruif, Robert P. Doornbos, Andres Sirulnik, Mark Throsby, Ton Logtenberg, Harry Dolstra, Alexander B. H. Bakker	47
3	The identification and characterization of a STAT5 gene signature in hematologic malignancies 2015 ·Cancer Biomarkers ·Dmitriy Sonkin, Michael R. Palmer, (unknown), (unknown), Catherine H. Régnier, Christie Fanton, Jocelyn Holash, Maria Pinzon-Ortiz, Matthew Squires, Andres Sirulnik, Thomas Radimerski, Robert Schlegel, Michael Morrissey, Z. Alexander Cao	7
4	A Multinational, Open-Label Phase 2 Study Of Ruxolitinib In Asian Patients (Pts) With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF) 2013 ·Blood ·Chul Won Jung, Lee‐Yung Shih, Zhijian Xiao, Jie Jin, Hsin‐An Hou, Xin Du, Ming‐Chung Wang, Seonyang Park, Ki‐Seong Eom, Kenji Oritani, Shinichiro Okamoto, Tetsuzo Tauchi, Jin Seok Kim, Daobin Zhou, Andres Sirulnik, (unknown), (unknown), Kazuo Itô, Koichi Akashi	11
5	Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis 2013 ·Blood ·Francisco Cervantes, Alessandro M. Vannucchi, Jean‐Jacques Kiladjian, Haifa Kathrin Al‐Ali, Andres Sirulnik, Viktoriya Stalbovskaya, Mari McQuitty, Deborah Hunter, Richard S. Levy, Francesco Passamonti, Tiziano Barbui, Giovanni Barosi, Claire Harrison, Laurent Knoops, Heinz Gisslinger	294
6	Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy 2013 ·British Journal of Haematology ·Claire Harrison, Ruben A. Mesa, Jean‐Jacques Kiladjian, Haifa Kathrin Al‐Ali, Heinz Gisslinger, Laurent Knoops, Margaret Squier, Andres Sirulnik, (unknown), Xiaolei Zhou, Catherine Copley‐Merriman, Deborah Hunter, Richard S. Levy, Francisco Cervantes, Francesco Passamonti, Tiziano Barbui, Giovanni Barosi, Alessandro M. Vannucchi	63
7	The Use of Erythropoietic-Stimulating Agents (ESAs) with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), and Post-Essential Thrombocythemia Myelofibrosis (PET-MF). 2012 ·Blood ·Mary Frances McMullin, Claire Harrison, Dietger Niederwieser, Hilde Demuynck, Nadja Jäkel, Andres Sirulnik, (unknown), Viktoriya Stalbovskaya, Christian Récher, Koen Theunissen, Heinz Gisslinger, Jean‐Jacques Kiladjian, (unknown)	12
8	Long-Term Safety, Efficacy, and Survival Findings From Comfort-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy (BAT) for the Treatment of Myelofibrosis (MF) 2012 ·Blood ·Francisco Cervantes, Jean‐Jacques Kiladjian, Dietger Niederwieser, Andres Sirulnik, Viktoriya Stalbovskaya, (unknown), Deborah Hunter, Richard S. Levy, Francesco Passamonti, Tiziano Barbui, Giovanni Barosi, Heinz Gisslinger, Alessandro M. Vannucchi, Laurent Knoops, Claire Harrison	39
9	Effect of Ruxolitinib On the Incidence of Splenectomy in Patients with Myelofibrosis: A Retrospective Analysis of Data From Ruxolitinib Clinical Trials. 2012 ·Blood ·Srđan Verstovšek, Jean‐Jacques Kiladjian, Ruben A. Mesa, Alessandro M. Vannucchi, Jason Gotlib, Giovanni Barosi, Hagop M. Kantarjian, Andres Sirulnik, Wei Peng, Victor Sandor, Claire Harrison	6
10	Expand: a Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib in Patients with Myelofibrosis and Baseline Platelet Counts Between 50 × 109/L and 99 × 109/L 2012 ·Blood ·Claire Harrison, Heinz Gisslinger, Carole B. Miller, Jean‐Jacques Kiladjian, (unknown), Viktoriya Stalbovskaya, Andres Sirulnik, Haifa Kathrin Al‐Ali, Giovanni Barosi, Mary Frances McMullin, Srđan Verstovšek, Alessandro M. Vannucchi	13
11	A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practices 2011 ·Annals of Oncology ·Peter W. T. Pisters, Charles D. Blanke, Margaret von Mehren, Joel Picus, Andres Sirulnik, (unknown), Jonathan C. Trent	27
12	Anemia and the Use of Erythropoietic-Stimulating Agents with Ruxolitinib in the COMFORT-II Study 2011 ·Blood ·Mary Frances McMullin, Claire Harrison, Dietger Niederwieser, Hilde Demuynck, (unknown), Andres Sirulnik, (unknown), Viktoriya Stalbovskaya, Jean‐Jacques Kiladjian, Haifa Kathrin Al‐Ali	1
13	Non-Adherence to Imatinib in Chronic Myeloid Leukemia Patients Is Associated with a Short Term and Long Term Negative Impact On Healthcare Utilization and Costs. 2009 ·Blood ·Eric Q. Wu, Vamsi Bollu, Amy Guo, Annie Guérin, Andrew P. Yu, Andres Sirulnik, James D. Griffin	8
14	Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous Leukemia 2008 ·Clinical Cancer Research ·Eyal C. Attar, Daniel J. DeAngelo, Jeffrey G. Supko, (unknown), David Zahrieh, Andres Sirulnik, Martha Wadleigh, Karen K. Ballen, (unknown), Kenneth B. Miller, James D. Levine, Ilene Galinsky, Elizabeth Trehu, David P. Schenkein, Donna Neuberg, Richard M. Stone, Philip C. Amrein	93
15	The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor 2007 ·Blood ·(unknown), Manabu Shimoyama, Hitomi Nishio, Julia A. Meyer, Dong Joon Min, Andres Sirulnik, (unknown), Marta Chesi, P. Leif Bergsagel, Ming‐Ming Zhou, Samuel Waxman, Boris A. Leibovitch, Martin J. Walsh, Jonathan D. Licht	157
16	A Phase I-II Pilot Study of Divalproex Sodium Alone and in Combination with All-Trans-Retinoic Acid (ATRA) in Relapsed or Refractory Acute Myeloid Leukemia. 2005 ·Blood ·Janice Gabrilove, (unknown), Windy Berkofsky‐Fessler, Andres Sirulnik, Sanjeev Sharma, Lewis R. Silverman, Luis Isola, John Mandeli, Jonathan D. Licht	1
17	Addition of Bortezomib (Velcade) to AML Induction Chemotherapy Is Well Tolerated and Results in a High Complete Remission Rate. 2005 ·Blood ·Eyal C. Attar, (unknown), Andres Sirulnik, Martha Wadleigh, Karen K. Ballen, Kenneth B. Miller, Ilene Galinsky, Donna Neuberg, Elizabeth Trehu, David P. Schenkein, Richard M. Stone, Philip C. Amrein	8
18	Molecular pathogenesis of acute promyelocytic leukaemia and APL variants 2003 ·Best Practice & Research Clinical Haematology ·Andres Sirulnik, Ari Melnick, Arthur Zelent, Jonathan D. Licht	37
19	A Phase II Study of Arsenic Trioxide in the Treatment of Relapsed and Refractory Low-Grade Lymphomas 2002 ·Blood ·Richard R. Furman, Andres Sirulnik, (unknown), Robin Brenner, Paolo Alberto Paciucci, Janice Gabrilove, Sergio Waxman	1
20	Hepatocyte growth factor/scatter factor (HGF/SF), the c-met receptor and the behaviour of epithelial cells. 1993 ·PubMed ·Ermanno Gherardi, Michka Sharpe, K. Lane, Andres Sirulnik, M. G. P. Stoker	60

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact